NCT03687580 (LLL&DIAB-02) is a NA clinical trial of B-Cure Laser Pro in Diabetic Foot Ulcer, sponsored by Scarborough Rouge Hospital.

Who is sponsoring NCT03687580?

NCT03687580 is sponsored by Scarborough Rouge Hospital.

What drugs are being tested in NCT03687580?

Interventions in NCT03687580: B-Cure Laser Pro, Sham laser.

What condition does NCT03687580 study?

NCT03687580 studies Diabetic Foot Ulcer.

Is NCT03687580 still recruiting?

NCT03687580 is currently recruiting now. Last updated 22 October 2024.

Last reviewed 2024-10-22 · How we verify

NCT03687580: LLL&DIAB-02

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Laser Therapy for At-Home Treatment of Diabetic Foot Ulcers - Canada

Recruiting now NA Last updated 22 October 2024

What this trial tests

NA trial testing B-Cure Laser Pro in Diabetic Foot Ulcer in 60 participants. Currently enrolling.

Timeline

1 February 2019

Primary endpoint
1 October 2025

1 October 2026

Quick facts

Lead sponsor	Scarborough Rouge Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	60
Start date	1 February 2019
Primary completion	1 October 2025
Estimated completion	1 October 2026
Sites	1 location across Canada

Drugs / interventions tested

B-Cure Laser Pro
Sham laser

Conditions studied

Diabetic Foot Ulcer — all drugs for Diabetic Foot Ulcer →

Sponsor

Scarborough Rouge Hospital

Who can join

Adults 18 to 95, any sex, with Diabetic Foot Ulcer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The global prevalence of diabetes is on the rise and with it increase in prevalence of diabetic foot ulcers (DFU). These recalcitrant wounds are difficult to manage and pose a heavy economic burden. Photobiomodulation (low level laser) is used for acceleration of wound healing. The current study is designed to evaluate the effectiveness of B-cure laser, a home-use low-level laser device, for acceleration of diabetic foot ulcer healing over standard treatment.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Diabetic Foot Ulcer

Currently open trials in the same condition.

NCT07161830 — Evaluating the Efficacy of OCM™ (Omeza® Complete Matrix) in the Treatment of Diabetic Foot Ulcers · NA · recruiting
NCT07396376 — Evaluation of ELU42 Topical Spray for the Treatment of Diabetic Foot Ulcers · Phase 1, PHASE2 · recruiting
NCT07291817 — Intermittent Negative Pressure for Patients With Diabetic Foot Ulcers (INPRESS) Study · NA · recruiting
NCT07209358 — EDX110 Randomized Control Trial for Treatment of DFUs · NA · recruiting
NCT06938685 — Evaluating the Efficacy NeoThelium FT in the Treatment of Diabetic Foot Ulcers · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03687580 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Scarborough Rouge Hospital
Last refreshed: 22 October 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03687580.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing